A single-arm, exploratory study of disitamab vedotin (DV) combined with camrelizumab and platinum-based chemotherapy as first-line treatment in patients with HER2 expressing locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Details

Language :

English

ISSN :

0732183X

Volume :

42

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

178967606

Full Text :

https://doi.org/10.1200/JCO.2024.42.23_suppl.TPS217